Skip to main content

Table 2 Univariate analysis of variables associated with 5-year OS and PFS (n = 424)

From: Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma

Prognostic factors

OS

PFS

Hazard ratio

95 % CI

p value

Hazard ratio

95 % CI

p value

LMR: high versus low

0.528

0.129–0.849

0.008

0.541

0.136–0.894

0.002

HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA

0.404

0.025–0.647

0.001

0.529

0.151–0.826

0.001

Age : ≤46 versus >46

0.452

0.121–0.837

0.014

0.412

0.087–1.030

0.040

FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA

0.197

0.018–0.416

0.034

0.484

0.0134–0.839

0.024

pathological type: SCC versus ADC versus ASC versus UDC

0.418

0.168–0.827

0.031

0.478

0.174–0.930

0.043

Lymph node status classification: positive lymph node versus negative lymph node

3.586

0.876–5.439

0.043

2.542

1.047–4.283

0.045

Treatment modality: IC + RT versus CCRT versus IC + CCRT

0.530

0.129–0.934

0.039

2.164

1.687–4.017

0.102

ALC: high versus low

0.571

0.292–0.843

0.002

0.513

0.385–0.738

0.008

AMC: high versus low

2.418

1.215–4.738

0.931

0.714

0.306–1.136

0.035

  1. OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count